Business · 27/10/2021Updated: 10/17/2026 · 1 min read
FDA Awards Priority Review Voucher to Enzyvant Therapeutics for Rare Pediatric Disease Product
Summary
The FDA has issued a priority review voucher to Enzyvant Therapeutics, the sponsor of a rare pediatric disease product application, RETHYMIC, which is manufactured by Enzyvant Therapeutics, GmbH.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →